FDA approval: Ryoncil (from Catapult's regulatory round-up for December 2024)
FDA has approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Steroid-refractory acute graft-versus-host disease is a serious and life-threatening condition that can occur as a complication of allogeneic hematopoietic (blood) stem cell transplantation (allo-HSCT). MSCs are a type of cell...
Publication Details
- Journal
- Industrias Culturais (Universidade de Coimbra)
- Published
- 2025-02-12
- DOI
- https://doi.org/10.58079/13axz
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00